Drug combination studies and their synergy quantification using the Chou-Talalay method
about
Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell lineA novel alternatively spliced isoform of the mu-opioid receptor: functional antagonismSynergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current ResearchNanodiamonds: The intersection of nanotechnology, drug development, and personalized medicineWhat is synergy? The Saariselkä agreement revisitedA cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinomaEngineering a Brain Cancer Chip for High-throughput Drug ScreeningThe BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their AlkalinizationDrosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate TherapeuticImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeVemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.Mutant HRAS as novel target for MEK and mTOR inhibitorsTargeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Synthetic lethality in lung cancer and translation to clinical therapiesImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysBiomolecular Network-Based Synergistic Drug Combination DiscoveryApplication of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identificationGeneration of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapyDual targeting of p53 and c-MYC selectively eliminates leukaemic stem cellsDual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activityArtesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosisCombination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cellsAn Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor XenograftsEffect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cellsHalofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivoPrediction of drug combinations by integrating molecular and pharmacological dataPristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cellsAstemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapySynergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studiesCombined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysActivity of oxantel pamoate monotherapy and combination chemotherapy against Trichuris muris and hookworms: revival of an old drugSynergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumorsApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaTargeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotideDB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOsA quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi
P2860
Q21134144-346B17F2-5C14-4CA5-8D5E-E237CB45929DQ24317131-CBB3A5F9-C667-42D7-B9C2-821EA96BDCADQ26741422-62C31B1F-0143-4173-93FA-978F125D413DQ26776095-586A670B-BA66-4F8A-952D-228E71C74DFDQ26782977-E315849C-D89E-4931-9E53-A48BC344BE37Q27307150-5F4C107A-92BF-4456-9852-D802614932D5Q27318558-CF3FFF68-EFCF-427A-8A46-878A7C55EE23Q27318794-B322C831-CD7B-4D30-AE9C-887F6AFF44AEQ27319935-0C060549-0791-4EF9-87A2-33AC71DF6906Q27334924-E20B378C-3B26-49FB-849E-A8EE10C19E3AQ27852401-BECF5720-A638-4119-9A7F-C22F54A4E3F2Q27852536-C6143696-142C-4DCB-B447-35EEA6BC9C40Q27853217-E29EEE51-F97A-4FA2-812B-2FE6C8C94939Q27853237-C732DFD3-AF94-414F-8B02-F195B383BBACQ27853238-943DAD33-C2BC-4641-95D5-66062E543D81Q27853330-BA2EFD54-8AE6-4397-872F-C04B6026D655Q28072904-E48C01D2-B796-4CA8-A4D6-45C400F9256BQ28077848-09EB658F-BBDC-40CD-BFE0-B6D628007D16Q28077880-01B60AF7-9F1E-44E9-9BB4-94C2C45F7F0EQ28077952-5A89F136-7F6E-4563-83BE-A7044519D832Q28269627-3CF12642-DF45-425A-A5C0-0255D3547961Q28276260-79E1AA30-8973-4538-AC37-8720201A9938Q28304985-F1330C03-17E7-45CB-99C7-A3E07F5903FEQ28393215-D5215ADC-951B-4309-838F-BF4CD1D435EDQ28395254-1A0929A6-2BCD-471B-A2DF-17A3665A6E63Q28468447-04199559-05A9-40BF-B397-B7AFFD37E6D4Q28468621-24D8D43C-67CB-4E85-BC14-94C49072ED23Q28468670-22FD864C-3F6E-434B-818F-874C631C2D0AQ28476362-65496499-8473-4C8F-8643-2361A9B9A8FBQ28478623-23E9C1BD-7100-4FC9-9DCC-648F9E1D079EQ28482913-C9C1FBB2-C151-4F83-910D-D2325740A1C1Q28483692-4A4BC93E-73CD-482F-843A-086F65A7299AQ28484167-3B0E750F-0651-40DD-BF57-15BDE1569441Q28484572-3E0485F7-E1AC-4624-BD0B-CCB6CD07692AQ28488644-DFD18543-CA2B-4384-9AEB-7D20A3B0598FQ28533752-86647047-9D9E-4ACC-AB71-5CA01758A4E3Q28534259-70A35B55-8CC1-4494-B4AD-A2AD059A7EA4Q28535212-461239CC-200A-4CFB-B7A2-87DB3074B285Q28535401-B42BF9BA-282F-4DED-80DC-58EAD24758B6Q28538813-27AEC2A7-EC38-4B95-BB5B-356FA210954D
P2860
Drug combination studies and their synergy quantification using the Chou-Talalay method
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug combination studies and their synergy quantification using the Chou-Talalay method
@ast
Drug combination studies and their synergy quantification using the Chou-Talalay method
@en
type
label
Drug combination studies and their synergy quantification using the Chou-Talalay method
@ast
Drug combination studies and their synergy quantification using the Chou-Talalay method
@en
prefLabel
Drug combination studies and their synergy quantification using the Chou-Talalay method
@ast
Drug combination studies and their synergy quantification using the Chou-Talalay method
@en
P3181
P1433
P1476
Drug combination studies and their synergy quantification using the Chou-Talalay method
@en
P2093
P3181
P356
10.1158/0008-5472.CAN-09-1947
P407
P577
2010-01-15T00:00:00Z